These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16989125)

  • 1. [Paediatric specificity of antifungals use].
    Tabone MD; Le Guyader N; Leverger G
    Therapie; 2006; 61(3):243-8. PubMed ID: 16989125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not Available].
    Tabone MD; Guyader NL; Leverger G
    Therapie; 2006; 61(3):243-8. PubMed ID: 27393523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on antifungal agents for paediatric patients.
    Groll AH; Tragiannidis A
    Clin Microbiol Infect; 2010 Sep; 16(9):1343-53. PubMed ID: 20678177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superficial mycoses in Belgium: Burden, costs and antifungal drugs consumption.
    Becker P; Lecerf P; Claereboudt J; Devleesschauwer B; Packeu A; Hendrickx M
    Mycoses; 2020 May; 63(5):500-508. PubMed ID: 32048335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of invasive fungal infections in neonates and children.
    Steinbach WJ
    Clin Microbiol Infect; 2010 Sep; 16(9):1321-7. PubMed ID: 20840541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics and pharmacodynamics of antifungal drugs in children].
    Jullien V
    Arch Pediatr; 2011 May; 18 Suppl 1():S42-7. PubMed ID: 21596286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to antifungal drugs in Madagascar. The situation in 2020.
    Grillot R; Ratsimbazafimahefa HMR; Ravelomampianina HSN
    J Mycol Med; 2021 Mar; 31(1):101120. PubMed ID: 33626442
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mycoses and antifungals: What is the situation in Senegal in the current context?].
    Diongue K; Ndiaye M; Seck MC; Diallo MA; Badiane AS; Ndiaye D
    Ann Pharm Fr; 2021 Jul; 79(4):440-445. PubMed ID: 33232707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology.
    des Champs-Bro B; Leroy-Cotteau A; Mazingue F; Pasquier F; François N; Corm S; Lemaitre L; Poulain D; Yakoub-Agha I; Alfandari S; Sendid B
    J Clin Pharm Ther; 2011 Apr; 36(2):152-60. PubMed ID: 21366643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection criteria for antifungals: the right patients and the right reasons.
    Chandrasekar P
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():17-20. PubMed ID: 16707246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nail disease: antifungals have similar cure rates, different side-effects.
    Dallimore KJ
    Australas J Dermatol; 1999 Nov; 40(4):235. PubMed ID: 10570567
    [No Abstract]   [Full Text] [Related]  

  • 12. Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help?
    Hull CM; Purdy NJ; Moody SC
    Future Microbiol; 2014; 9(3):307-25. PubMed ID: 24762306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends of Antifungal Use Based on Sales Data in Japan from 2006 to 2015.
    Kawabe A; Muraki Y; Inose R; Kusama Y; Goto R; Ebisui A; Ishii S; Ishikane M; Ohge H; Ohmagari N
    Biol Pharm Bull; 2020; 43(8):1248-1252. PubMed ID: 32741945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
    Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal agents and immunomodulators in systemic mycoses.
    Khan ZK; Jain P
    Indian J Chest Dis Allied Sci; 2000; 42(4):345-55. PubMed ID: 15597684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions.
    Johnson MD; Kleinberg M; Danziger L; Ostrosky-Zeichner L
    Expert Opin Pharmacother; 2005 Dec; 6(15):2617-32. PubMed ID: 16316301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections.
    Lewis RE
    Am J Ther; 2012 Jan; 19(1):51-63. PubMed ID: 21248618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ototopical antifungals and otomycosis: a review.
    Munguia R; Daniel SJ
    Int J Pediatr Otorhinolaryngol; 2008 Apr; 72(4):453-9. PubMed ID: 18279975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress on antifungal drug development.
    Zhai B; Lin X
    Curr Pharm Biotechnol; 2011 Aug; 12(8):1255-62. PubMed ID: 21470148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posaconazole for paediatric patients: status of development and future perspectives.
    Groll AH; Lehrnbecher T
    Mycoses; 2008 Sep; 51 Suppl 2():5-11. PubMed ID: 18721328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.